VistaGen Therapeutics VTGN 深 沪
已收盘 08-01 16:00:00 美东时间
2.92
+0.050
+1.74%
华盛通- 最 高2.9403
- 今 开2.84
- 成交量 32.96万股
- 最 低 2.70
- 昨 收 2.87
- 总市值 8514.05万
- 52周最高 3.79
- 市盈率 静 --
- 换手率 1.13%
- 52周最低 1.90
- 委 比 -23.08%
- 总股本 2915.77万
- 历史最高 495.00
- 量 比 0.44
- 振 幅 8.37%
- 历史最低 1.90
- 每 手 1
- 风险率 0.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vistagen Appoints Elissa Cote as Chief Development Officer
VistaGen Therapeutics ( ($VTGN) ) has provided an announcement. On June 25, 202...
06-26 05:17
Vistagen Therapeutics Reports Progress in Clinical Trials
Vistagen Therapeutics Inc. ( ($VTGN) ) has released its Q4 earnings. Here is a ...
06-18 11:52
Earnings Scheduled For June 17, 2025
Companies Reporting Before The Bell • Tsakos Energy Navigation (NYSE:TEN) is es...
06-17 16:32
Insights into VistaGen Therapeutics's Upcoming Earnings
VistaGen Therapeutics (NASDAQ:VTGN) is gearing up to announce its quarterly ear...
06-16 22:02
Vistagen Therapeutics Provides Update For U.S. Registration-Directed PALISADE-3 Phase 3 Trial Evaluating Fasedienol For Acute Treatment Of Social Anxiety Disorder
Company's PALISADE-4 Phase 3 trial now expected to read out in the first half of 2026
06-02 20:34
VistaGen’s Earnings Call: Progress and Challenges
Vistagen Therapeutics Inc. (($VTGN)) has held its Q3 earnings call. Read on for...
02-15 08:10
VistaGen Reports Q3 2025 Financial Results and Updates
VistaGen Therapeutics ( ($VTGN) ) has provided an announcement. On February 13,...
02-14 06:18
VistaGen Therapeutics Q3 EPS $(0.46) Beats $(0.51) Estimate, Sales $234.00K Beat $180.00K Estimate
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.51) by 9.8 percent. This is a 109.09 percent decrease over losses of $(0.22) per share
02-14 05:42
VistaGen Therapeutics Advances Neurocircuitry Treatments
An announcement from VistaGen Therapeutics ( ($VTGN) ) is now available. Vistag...
2024-12-07 06:18
